Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer

ABSTRACT: Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer

PROVIDER: PRJNA752351 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15353270.fastq.gz	Fastqsanger.gz
	SRR15353270_1.fastq.gz	Fastqsanger.gz
	SRR15353270_2.fastq.gz	Fastqsanger.gz
	SRR15353271_1.fastq.gz	Fastqsanger.gz
	SRR15353271_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 17

Similar Datasets

Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer

Project description:To explore how DOCK1 deficiency enhances the anti-tumor effects of metformin, we performed RNA-seq analysis in PLC cells expressing NTC or shDOCK1 in the presence or absence of metformin.

2021-12-31 | GSE181521 | GEO

CRISPR-Cas9 RBM10 synthetic lethality screen

Project description:Genome-wide CRISPR-Cas9 knockout screen using TKOv1 sgRNA library was performed in isogenic RBM10-proficient and RBM10-deficient HCC827 cells.

2023-03-04 | E-MTAB-12724 | biostudies-arrayexpress

Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer.

Project description:Metformin is currently a strong candidate anti-tumor agent in multiple cancers. However, its anti-tumor effectiveness varies among different cancers or subpopulations, potentially due to tumor heterogeneity. It thus remains unclear which hepatocellular carcinoma (HCC) patient subpopulation(s) can benefit from metformin treatment. Here, through a genome-wide CRISPR-Cas9-based knockout screen, we find that DOCK1 levels determine the anti-tumor effects of metformin and that DOCK1 is a synthetic lethal target of metformin in HCC. Mechanistically, metformin promotes DOCK1 phosphorylation, which activates RAC1 to facilitate cell survival, leading to metformin resistance. The DOCK1-selective inhibitor, TBOPP, potentiates anti-tumor activity by metformin in vitro in liver cancer cell lines and patient-derived HCC organoids, and in vivo in xenografted liver cancer cells and immunocompetent mouse liver cancer models. Notably, metformin improves overall survival of HCC patients with low DOCK1 levels but not among patients with high DOCK1 expression. This study shows that metformin effectiveness depends on DOCK1 levels and that combining metformin with DOCK1 inhibition may provide a promising personalized therapeutic strategy for metformin-resistant HCC patients.

| S-EPMC9237198 | biostudies-literature

SGS1 synthetic lethality

Project description:Assessment of synthetic lethality between an sgs1 null mutation and Yeast Deletion mutations Keywords = SGS1 Keywords = yeast Keywords = deletion Keywords = synthetic lethality Keywords = tag Keywords = barcode Keywords: repeat sample

2004-11-05 | GSE1757 | GEO

BIM1 synthetic lethality

Project description:Assessment of synthetic lethality between a bim1 null mutation and Yeast Deletion mutations Keywords = BIM1 Keywords = yeast Keywords = deletion Keywords = synthetic lethality Keywords = tag Keywords = barcode Keywords: repeat sample

2004-11-05 | GSE1756 | GEO

CIN8 Synthetic Lethality

Project description:Assessment of synthetic lethality between a cin8 deletion mutation and Yeast Deletion mutations. Keywords = CIN8 Keywords = yeast Keywords = deletion Keywords = synthetic lethality Keywords = tag Keywords = barcode Keywords: repeat sample

2004-11-05 | GSE1754 | GEO

SML1 synthetic lethality

Project description:Assessment of synthetic lethality between an sml1 null mutation and Yeast Deletion mutations Keywords = SML1 Keywords = yeast Keywords = deletion Keywords = synthetic lethality Keywords = tag Keywords = barcode Keywords: repeat sample

2004-11-05 | GSE1765 | GEO

Genome-wide screen unveils the synthetic lethality targets of mitomycin C

Project description:To dig out the synthetic lethality targets of mitomycin C, we we performed Genome-scale CRISPR-Cas9 knockout screening in SNU-1 with 0.1% DMSO or 0.3 µM MMC for 14 days. We found that BRCA2 is a synthetic lethality target of mitomycin C.

2022-06-08 | GSE132431 | GEO

LCD1-overexpression synthetic lethality

Project description:Assessment of synthetic lethality between an overexpressed LCD1 gene and Yeast Deletion mutations Keywords = LCD1 Keywords = overexpression Keywords = yeast Keywords = deletion Keywords = synthetic lethality Keywords = tag Keywords = barcode Keywords: repeat sample

2004-11-05 | GSE1759 | GEO

Genome-wide screen unveils the synthetic lethality targets of mitomycin C

Project description:Genome-wide screen unveils the synthetic lethality targets of mitomycin C

| PRJNA548076 | ENA